Molluscum Contagiosum Clinical Trial
Official title:
Efficacy and Tolerance of the Topical Application of Potassium Hydroxide (10% and 15%) in the Treatment of Molluscum Contagiosum
BACKGROUND:
Molluscum contagiosum is a non-serious children viral infection. Because of its natural
history, being highly contagious and the aesthetic and psychotherapeutic effects of its
treatment, the investigators intend to test the use of different concentrations of potassium
hydroxide solution in the primary care setting.
METHODS:
A double blind, randomized clinical trial, in three groups of topic treatment is designed.
The intended treatment consists on a daily application of potassium hydroxide in aqueous
solution at 10% and 15% concentration, versus a placebo administered to the control group. 4
follow-up visits (15, 30, 45 and 60 days) are planned to evaluate treatment effectiveness
and tolerance.
The main target of the trial is to determine the healing rate, defined as lesion
disappearance in the affected zones after the topic application of the treatment. Secondary
targets are the main characteristics and evolution of the affected zone (surface, number of
lesions, size and density) description, tolerance evaluation (hyperpigmentation, itching,
burning, pain), recurrence rate estimation and natural evolution of lesions in the control
group.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03017846 -
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
|
Phase 2 | |
| Recruiting |
NCT05937672 -
Cold Atmospheric Plasma Device Extension Study
|
Phase 3 | |
| Completed |
NCT04535531 -
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
|
Phase 3 | |
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
| Completed |
NCT05897112 -
Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum
|
Phase 1 | |
| Withdrawn |
NCT05536882 -
MC RCT - BPO vs Adapalene
|
Phase 3 | |
| Completed |
NCT03377790 -
Cantharidin Application in Molluscum Patients-1
|
Phase 3 | |
| Completed |
NCT05634460 -
Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum
|
Phase 1 | |
| Completed |
NCT03186378 -
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
|
Phase 2 | |
| Completed |
NCT03927716 -
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
|
Phase 3 | |
| Recruiting |
NCT04476186 -
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
|
N/A | |
| Completed |
NCT03927703 -
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
|
Phase 3 | |
| Completed |
NCT02665260 -
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
| Completed |
NCT03436615 -
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
|
Phase 2 | |
| Recruiting |
NCT02759900 -
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
|
N/A | |
| Completed |
NCT05680181 -
Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
|
||
| Completed |
NCT03077750 -
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
|
Phase 2 | |
| Terminated |
NCT02024581 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
| Completed |
NCT03377803 -
Cantharidin Application in Molluscum Patients
|
Phase 3 | |
| Withdrawn |
NCT03336372 -
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
|
Early Phase 1 |